Clinical trial
Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00367497 is registered in ClinicalTrials.gov with Keio University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
- Lead sponsor
- Keio University
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2005
- Completion date
- November 30, 2007
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.